Sima Garberyte

Sima Garberyte

Auto-generated profile, based on publicly available information

Sima Garberyte

Department of Immunology, State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
AUA. Unguryte
A. Unguryte
EBE. Bernotiene
E. Bernotiene
EBE. Bagdonas
E. Bagdonas
SGS. Garberyte
S. Garberyte
NPN. Porvaneckas
N. Porvaneckas
Christian JorgensenChristian Jorgensen
Christian Jorgensen

27 November 2018 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
AMAgata Mlynska
Agata Mlynska
GSGreta Salciuniene
Greta Salciuniene
KZKarolina Zilionyte
Karolina Zilionyte
SGSima Garberyte
Sima Garberyte
MSMarius Strioga
Marius Strioga
VPVita Pasukoniene
Vita Pasukoniene
The management of advanced ovarian cancer is challenging due to the high frequency of recurrence, often associated with the development of resistance to platinum-based chemotherapy. Molecular analyses revealed the complexity of ovarian cancer with particular emphasis on the immune system, which may contribute to disease progression and response to treatment. Cytokines and chemokines mediate the cross-talk between cancer and immune cells, and therefore, present as potential biomarkers, reflecting the tumor microenvironment. A panel of circulating C-C motif chemokine ligand (CCL) and C-X-C motif chemokine ligand (CXCL) chemokines were examined in the serum of 40 high-grade patients with ovarian cancer prior to primary surgery. The level of immune infiltration in tumors was also analyzed. The preoperative levels of chemokines differ between patients. Elevated levels of circulating CXCL4 + CCL20 + CXCL1 combination can discriminate patients with shorter recurrence-free survival and overall survival. The presence of tumor-infiltrating T lymphocytes was detected in half of the patients. The mRNA expression analysis suggests the presence of antitumoral and immunosuppressive elements in the tumor microenvironment. The combination of circulating CXCL9 + CXCL10 can distinguish immune-infiltrated tumors that will lead to shorter recurrence-free survival. The results suggest that preoperative profiling of circulating chemokines in patients with ovarian cancer may provide valuable information regarding tumor recurrence and immune infiltration. The findings demonstrate that combinations have better prognostic utility than single chemokines, and may serve as patient stratification tools.

1 January 2020 in Journal of Cancer
Verified
Journal Article
Open access
GZGintaras Zaleskis
Gintaras Zaleskis
SGSima Garberytė
Sima Garberytė
BPBožena Pavliukevičienė
Božena Pavliukevičienė
GVGintaras Valincius
Gintaras Valincius
DCDainius Characiejus
Dainius Characiejus
VPVita Pašukonienė
Vita Pašukonienė
Background/Aims: Chemotherapy resistance of malignancies is a universal phenomenon which unfavorably affects therapeutic results. Genetic adaptations as well as epigenetic factors can play an important role in the development of multidrug resistance. Cytotoxic drug content in plasma of cancer patients is known to variate up to one hundred-fold regardless of the same dose injected per m2 body surface. The relationship between plasma concentrations, tissue uptake, and chemotherapy response is not completely understood. The main objective of this study was to investigate how the identical dose of Doxorubicin (Dox) can result in a different therapeutic response pattern depending on tumor size.